Abstract:Stroke remains one of the main causes of mortality and morbidity worldwide. Immediately after stroke, a neuroinflammatory process starts in the brain, triggering a systemic immunodepression mainly through excessive activation of the autonomous nervous system. Manifestations of immunodepression include lymphopenia but also dysfunctional innate and adaptive immune cells. The resulting impaired antibacterial defenses render patients with stroke susceptible to infections. In addition, other risk factors like stroke severity, dysphagia, impaired consciousness, mechanical ventilation, catheterization, and older age predispose stroke patients for infections. Most common infections are pneumonia and urinary tract infection, both occur in ≈10% of the patients. Especially pneumonia increases unfavorable outcome and mortality in patients with stroke; systemic effects like hypotension, fever, delay in rehabilitation are thought to play a crucial role. Experimental and clinical data suggest that systemic infections enhance autoreactive immune responses against brain antigens and thus negatively affect outcome but convincing evidence is lacking. Prevention of poststroke infections by preventive antibiotic therapy did not improve functional outcome after stroke. Immunomodulatory approaches counteracting immunodepression to prevent stroke-associated pneumonia need to account for neuroinflammation in the ischemic brain and avoid further tissue damage. Experimental studies discovered interesting targets, but these have not yet been investigated in patients with stroke. A better understanding of the pathobiology may help to develop optimized approaches of preventive antibiotic therapy or immunomodulation to effectively prevent stroke-associated pneumonia while improving long-term outcome after stroke. In this review, we aim to characterize epidemiology, risk factors, cause, diagnosis, clinical presentation, and potential treatment of poststroke immunosuppression and associated infections.

Contribution of the immune response to stroke provides promising directions for future stroke immunotherapies

Systemic immune responses after ischemic stroke: From the center to the periphery

Targeting Neutrophils in Ischemic Stroke: Translational Insights from Experimental Studies

Immunothrombosis in Acute Ischemic Stroke

Focused Update on Stroke Neuroimmunology: Current Progress in Preclinical and Clinical Research and Recent Mechanistic Insight.

Glial Cells: Role of the Immune Response in Ischemic Stroke

Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke

Inflammatory mechanisms in ischemic stroke: therapeutic approaches

Perspective Review of Myeloid Immune Cell Responses and Poststroke Immunosuppression

The Evolving Role of Neuro-Immune Interaction in Brain Repair after Cerebral Ischemic Stroke

The immune response of T cells and therapeutic targets related to regulating the levels of T helper cells after ischaemic stroke

A Review of Future Therapies

Research progress on immune-related therapeutic targets of brain injury caused by cerebral ischemia

Potential Immunotherapeutic Targets on Myeloid Cells for Neurovascular Repair after Ischemic Stroke

Immunodepression, Infections, and Functional Outcome in Ischemic Stroke.

Thrombo-Inflammation and Immunological Response in Ischemic Stroke: Focusing on Platelet-Tregs Interaction

Updates of the role of B-cells in ischemic stroke

T Cell Response in Ischemic Stroke: From Mechanisms to Translational Insights

Stroke-induced Immunological Alterations and Relevant Treatment Strategies

Mechanisms of immune response and cell death in ischemic stroke and their regulation by natural compounds

Neuroprotection and Beyond: The Central Role of CB1 and CB2 Receptors in Stroke Recovery